---
_id: '13232'
abstract:
- lang: eng
  text: The potential of immune-evasive mutation accumulation in the SARS-CoV-2 virus
    has led to its rapid spread, causing over 600 million confirmed cases and more
    than 6.5 million confirmed deaths. The huge demand for the rapid development and
    deployment of low-cost and effective vaccines against emerging variants has renewed
    interest in DNA vaccine technology. Here, we report the rapid generation and immunological
    evaluation of novel DNA vaccine candidates against the Wuhan-Hu-1 and Omicron
    variants based on the RBD protein fused with the Potato virus X coat protein (PVXCP).
    The delivery of DNA vaccines using electroporation in a two-dose regimen induced
    high-antibody titers and profound cellular responses in mice. The antibody titers
    induced against the Omicron variant of the vaccine were sufficient for effective
    protection against both Omicron and Wuhan-Hu-1 virus infections. The PVXCP protein
    in the vaccine construct shifted the immune response to the favorable Th1-like
    type and provided the oligomerization of RBD-PVXCP protein. Naked DNA delivery
    by needle-free injection allowed us to achieve antibody titers comparable with
    mRNA-LNP delivery in rabbits. These data identify the RBD-PVXCP DNA vaccine platform
    as a promising solution for robust and effective SARS-CoV-2 protection, supporting
    further translational study.
acknowledgement: The authors declare that this study received funding from Immunofusion.
  The funder was not involved in the study design, collection, analysis, interpretation
  of data, the writing of this article, or the decision to submit it for publication.
  The authors express their gratitude to the Institute of Physiology of the National
  Academy of Sciences of Belarus for providing assistance in keeping laboratory animals.
article_number: '1014'
article_processing_charge: No
article_type: original
author:
- first_name: Dmitri
  full_name: Dormeshkin, Dmitri
  last_name: Dormeshkin
- first_name: Mikalai
  full_name: Katsin, Mikalai
  last_name: Katsin
- first_name: Maria
  full_name: Stegantseva, Maria
  last_name: Stegantseva
- first_name: Sergey
  full_name: Golenchenko, Sergey
  last_name: Golenchenko
- first_name: Michail
  full_name: Shapira, Michail
  last_name: Shapira
- first_name: Simon
  full_name: Dubovik, Simon
  last_name: Dubovik
- first_name: Dzmitry
  full_name: Lutskovich, Dzmitry
  last_name: Lutskovich
- first_name: Anton
  full_name: Kavaleuski, Anton
  id: 62304f89-eb97-11eb-a6c2-8903dd183976
  last_name: Kavaleuski
  orcid: 0000-0003-2091-526X
- first_name: Alexander
  full_name: Meleshko, Alexander
  last_name: Meleshko
citation:
  ama: Dormeshkin D, Katsin M, Stegantseva M, et al. Design and immunogenicity of
    SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein. <i>Vaccines</i>. 2023;11(6).
    doi:<a href="https://doi.org/10.3390/vaccines11061014">10.3390/vaccines11061014</a>
  apa: Dormeshkin, D., Katsin, M., Stegantseva, M., Golenchenko, S., Shapira, M.,
    Dubovik, S., … Meleshko, A. (2023). Design and immunogenicity of SARS-CoV-2 DNA
    vaccine encoding RBD-PVXCP fusion protein. <i>Vaccines</i>. MDPI. <a href="https://doi.org/10.3390/vaccines11061014">https://doi.org/10.3390/vaccines11061014</a>
  chicago: Dormeshkin, Dmitri, Mikalai Katsin, Maria Stegantseva, Sergey Golenchenko,
    Michail Shapira, Simon Dubovik, Dzmitry Lutskovich, Anton Kavaleuski, and Alexander
    Meleshko. “Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP
    Fusion Protein.” <i>Vaccines</i>. MDPI, 2023. <a href="https://doi.org/10.3390/vaccines11061014">https://doi.org/10.3390/vaccines11061014</a>.
  ieee: D. Dormeshkin <i>et al.</i>, “Design and immunogenicity of SARS-CoV-2 DNA
    vaccine encoding RBD-PVXCP fusion protein,” <i>Vaccines</i>, vol. 11, no. 6. MDPI,
    2023.
  ista: Dormeshkin D, Katsin M, Stegantseva M, Golenchenko S, Shapira M, Dubovik S,
    Lutskovich D, Kavaleuski A, Meleshko A. 2023. Design and immunogenicity of SARS-CoV-2
    DNA vaccine encoding RBD-PVXCP fusion protein. Vaccines. 11(6), 1014.
  mla: Dormeshkin, Dmitri, et al. “Design and Immunogenicity of SARS-CoV-2 DNA Vaccine
    Encoding RBD-PVXCP Fusion Protein.” <i>Vaccines</i>, vol. 11, no. 6, 1014, MDPI,
    2023, doi:<a href="https://doi.org/10.3390/vaccines11061014">10.3390/vaccines11061014</a>.
  short: D. Dormeshkin, M. Katsin, M. Stegantseva, S. Golenchenko, M. Shapira, S.
    Dubovik, D. Lutskovich, A. Kavaleuski, A. Meleshko, Vaccines 11 (2023).
date_created: 2023-07-16T22:01:10Z
date_published: 2023-06-01T00:00:00Z
date_updated: 2023-08-02T06:31:19Z
day: '01'
ddc:
- '570'
department:
- _id: LeSa
doi: 10.3390/vaccines11061014
external_id:
  isi:
  - '001017740000001'
file:
- access_level: open_access
  checksum: 8f484c0f30f8699c589b1c29a0fd7d7f
  content_type: application/pdf
  creator: dernst
  date_created: 2023-07-18T07:25:43Z
  date_updated: 2023-07-18T07:25:43Z
  file_id: '13244'
  file_name: 2023_Vaccines_Dormeshkin.pdf
  file_size: 2339746
  relation: main_file
  success: 1
file_date_updated: 2023-07-18T07:25:43Z
has_accepted_license: '1'
intvolume: '        11'
isi: 1
issue: '6'
language:
- iso: eng
month: '06'
oa: 1
oa_version: Published Version
publication: Vaccines
publication_identifier:
  eissn:
  - 2076-393X
publication_status: published
publisher: MDPI
quality_controlled: '1'
scopus_import: '1'
status: public
title: Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion
  protein
tmp:
  image: /images/cc_by.png
  legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
  name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
  short: CC BY (4.0)
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 11
year: '2023'
...
---
_id: '11462'
abstract:
- lang: eng
  text: Nanobodies (VHH) from camelid antibody libraries hold great promise as therapeutic
    agents and components of immunoassay systems. Synthetic antibody libraries that
    could be designed and generated once and for various applications could yield
    binders to virtually any targets, even for non-immunogenic or toxic ones, in a
    short term. One of the most difficult tasks is to obtain antibodies with a high
    affinity and specificity to polyglycosylated proteins. It requires antibody libraries
    with extremely high functional diversity and the use of sophisticated selection
    techniques. Here we report a development of a novel sandwich immunoassay involving
    a combination of the synthetic library-derived VHH-Fc fusion protein as a capture
    antibody and the immune single-chain fragment variable (scFv) as a tracer for
    the detection of pregnancy-associated glycoprotein (PAG) of cattle (Bos taurus).
    We succeeded in the generation of a number of specific scFv antibodies against
    PAG from the mouse immune library. Subsequent selection using the immobilized
    scFv-Fc capture antibody allowed to isolate 1.9 nM VHH binder from the diverse
    synthetic library without any overlapping with the capture antibody binding site.
    The prototype sandwich ELISA based on the synthetic VHH and the immune scFv was
    established. This is the first successful example of the combination of synthetic
    and immune antibody libraries in a single sandwich immunoassay. Thus, our approach
    could be used for the express isolation of antibody pairs and the development
    of sandwich immunoassays for challenging antigens.
acknowledgement: This study was financially supported by the State Committee on Science
  and Technology. We would like to thank Elena Tumar and Elena Kisileva at the Institute
  of Bioorganic Chemistry of NASB for their kind assistance with mouse immunizations.
article_processing_charge: No
article_type: original
author:
- first_name: Dmitri
  full_name: Dormeshkin, Dmitri
  last_name: Dormeshkin
- first_name: Michail
  full_name: Shapira, Michail
  last_name: Shapira
- first_name: Alena
  full_name: Karputs, Alena
  last_name: Karputs
- first_name: Anton
  full_name: Kavaleuski, Anton
  id: 62304f89-eb97-11eb-a6c2-8903dd183976
  last_name: Kavaleuski
  orcid: 0000-0003-2091-526X
- first_name: Ivan
  full_name: Kuzminski, Ivan
  last_name: Kuzminski
- first_name: Elena
  full_name: Stepanova, Elena
  last_name: Stepanova
- first_name: Andrei
  full_name: Gilep, Andrei
  last_name: Gilep
citation:
  ama: Dormeshkin D, Shapira M, Karputs A, et al. Combining of synthetic VHH and immune
    scFv libraries for pregnancy-associated glycoproteins ELISA development. <i>Applied
    Microbiology and Biotechnology</i>. 2022;106:5093-5103. doi:<a href="https://doi.org/10.1007/s00253-022-12022-w">10.1007/s00253-022-12022-w</a>
  apa: Dormeshkin, D., Shapira, M., Karputs, A., Kavaleuski, A., Kuzminski, I., Stepanova,
    E., &#38; Gilep, A. (2022). Combining of synthetic VHH and immune scFv libraries
    for pregnancy-associated glycoproteins ELISA development. <i>Applied Microbiology
    and Biotechnology</i>. Springer Nature. <a href="https://doi.org/10.1007/s00253-022-12022-w">https://doi.org/10.1007/s00253-022-12022-w</a>
  chicago: Dormeshkin, Dmitri, Michail Shapira, Alena Karputs, Anton Kavaleuski, Ivan
    Kuzminski, Elena Stepanova, and Andrei Gilep. “Combining of Synthetic VHH and
    Immune ScFv Libraries for Pregnancy-Associated Glycoproteins ELISA Development.”
    <i>Applied Microbiology and Biotechnology</i>. Springer Nature, 2022. <a href="https://doi.org/10.1007/s00253-022-12022-w">https://doi.org/10.1007/s00253-022-12022-w</a>.
  ieee: D. Dormeshkin <i>et al.</i>, “Combining of synthetic VHH and immune scFv libraries
    for pregnancy-associated glycoproteins ELISA development,” <i>Applied Microbiology
    and Biotechnology</i>, vol. 106. Springer Nature, pp. 5093–5103, 2022.
  ista: Dormeshkin D, Shapira M, Karputs A, Kavaleuski A, Kuzminski I, Stepanova E,
    Gilep A. 2022. Combining of synthetic VHH and immune scFv libraries for pregnancy-associated
    glycoproteins ELISA development. Applied Microbiology and Biotechnology. 106,
    5093–5103.
  mla: Dormeshkin, Dmitri, et al. “Combining of Synthetic VHH and Immune ScFv Libraries
    for Pregnancy-Associated Glycoproteins ELISA Development.” <i>Applied Microbiology
    and Biotechnology</i>, vol. 106, Springer Nature, 2022, pp. 5093–103, doi:<a href="https://doi.org/10.1007/s00253-022-12022-w">10.1007/s00253-022-12022-w</a>.
  short: D. Dormeshkin, M. Shapira, A. Karputs, A. Kavaleuski, I. Kuzminski, E. Stepanova,
    A. Gilep, Applied Microbiology and Biotechnology 106 (2022) 5093–5103.
date_created: 2022-06-26T22:01:34Z
date_published: 2022-08-01T00:00:00Z
date_updated: 2023-10-10T07:15:02Z
day: '01'
department:
- _id: GradSch
- _id: LeSa
doi: 10.1007/s00253-022-12022-w
external_id:
  isi:
  - '000813677500001'
  pmid:
  - '35723693'
intvolume: '       106'
isi: 1
language:
- iso: eng
month: '08'
oa_version: None
page: 5093-5103
pmid: 1
publication: Applied Microbiology and Biotechnology
publication_identifier:
  eissn:
  - 1432-0614
  issn:
  - 0175-7598
publication_status: published
publisher: Springer Nature
quality_controlled: '1'
scopus_import: '1'
status: public
title: Combining of synthetic VHH and immune scFv libraries for pregnancy-associated
  glycoproteins ELISA development
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 106
year: '2022'
...